Intelligent Bio Solutions Inc - INBS STOCK NEWS

Intelligent Bio Solutions (NASDAQ: INBS) has integrated Arabic language support into its Intelligent Fingerprinting Drug Screening System, marking its second international language integration. This strategic move follows the company's early 2025 Middle East expansion plans through partnership with Ivy Diagnostics.

The Arabic integration targets approximately 450 million Arabic speakers across 25 countries, particularly focusing on safety-critical industries, law enforcement, and drug rehabilitation sectors. With the workplace drug testing market in Saudi Arabia projected to reach $64.5 million by 2030, this update enhances accessibility for Arabic-speaking organizations.

This development follows INBS's recent FDA 510(k) submission in December 2024 and planned U.S. market entry in 2025, supporting the company's global expansion strategy across North and South America, Europe, Asia Pacific, and the Middle East, building on its presence in 19 countries.

Intelligent Bio Solutions (NASDAQ: INBS) announced its gold sponsorship at the 2025 National Drug and Alcohol Screening Association (NDASA) Conference, scheduled for April 1-4 in Jacksonville, Florida. Daniel Brown, Head of Clinical Affairs, will present the company's Intelligent Fingerprinting Drug Testing Solution on April 1.

The technology offers a portable, non-invasive drug screening method using fingerprint sweat, providing an alternative to traditional testing approaches. The company currently serves over 400 accounts across 19 countries in sectors including construction, transportation, mining, and manufacturing.

INBS is preparing to enter the U.S. drug screening market later this year, using the NDASA conference as a platform to engage with industry stakeholders and showcase their solution's relevance to the U.S. market.

Intelligent Bio Solutions (INBS) has expanded its fingerprint drug testing presence in Spain and Andorra through a strategic partnership with Detecto, a division of MTB Distribuciones Tecnologicas SL. The collaboration targets the Spanish drug testing market, projected to reach $448 million by 2030.

Major clients including Metro Barcelona and a large Rio Tinto-based mine currently require 1,000 drug testing cartridges monthly. The system has gained acceptance due to its non-invasive nature, easy collection process, and reduced maintenance costs through yearly calibration.

Detecto is expanding its focus to include law enforcement, rehabilitation, and maritime sectors, while seeing growth opportunities in ports, mining, and transportation. The partnership aims to leverage both companies' strengths to expand fingerprint sweat-based drug testing across various sectors.

Intelligent Bio Solutions (INBS) has secured its sixth U.S. patent (No. 12259385) for its Intelligent Fingerprinting Drug Screening Cartridge technology. The patent specifically protects the proprietary lateral flow test strip inside the screening cartridge, ensuring protection for all current and future screening products under U.S. intellectual property law.

The company's innovative technology uses fingerprint sweat analysis to detect common drugs of abuse, offering a non-invasive solution for safety-sensitive industries. This development strengthens INBS's competitive position as it prepares to enter the multi-billion dollar U.S. market in 2025.

Following its FDA 510(k) submission in December 2024, INBS is positioning itself to capitalize on the growing global drug screening market. The patent adds to the company's existing IP portfolio, which includes patents for their Sample Collection Cartridge, cartridge housing, and buffer clip design.

Intelligent Bio Solutions (NASDAQ: INBS) provided an update on its FDA clearance process for the Intelligent Fingerprint Drug Screening System, confirming its planned 2025 U.S. launch remains on track. The company submitted its 510(k) premarket notification on December 18, 2024, for its opiate test system, classified as a Class II device.

The submission included performance data showing 94.1% accuracy and Pharmacokinetic (PK) study results demonstrating fingerprint sweat's reliability for drug detection. The FDA has issued an Additional Information (AI) request, temporarily pausing the 90-day review period. While FDA clearance typically takes 3-6 months, the process may extend if additional data is required.

The system is currently operational in 19 countries with over 400 accounts globally. INBS plans to pursue FDA clearance for additional drug classes on its panel while preparing for entry into the U.S. market.

Intelligent Bio Solutions (INBS) announced the anticipated receipt of its sixth U.S. patent, strengthening protection for its lateral flow technology used in the Intelligent Fingerprinting Drug Testing Solution. The patent will safeguard the company's unique fingerprint sweat-based drug screening technology.

The expected patent grant comes as INBS advances its U.S. market entry strategy planned for 2025. The company's proprietary non-invasive drug testing technology addresses growing demand for workplace safety and compliance solutions. INBS has recently submitted an FDA 510(k) application and aims to expand its global market presence with this innovative sweat-based approach to drug screening.

Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company focused on intelligent, rapid, non-invasive testing solutions, has announced its participation in the upcoming iAccess Alpha Virtual Best Ideas Spring Conference 2025.

The conference is scheduled for March 25-26, 2025, with INBS management's presentation set for Tuesday, March 25th at 11:00 a.m. ET. The presentation will be accessible via webcast. Additionally, the company will conduct one-on-one meetings during the conference, which interested parties can schedule through iAccess representatives or by contacting KCSA Strategic Communications.

Intelligent Bio Solutions (Nasdaq: INBS) has completed its previously announced underwritten public offering, raising approximately $3.0 million in gross proceeds. The offering consisted of 1,500,000 shares of common stock priced at $2.00 per share, including the full exercise of the underwriter's option to purchase an additional 195,652 shares.

Ladenburg Thalmann & Co. Inc. served as the sole bookrunning manager for the offering, which was conducted under a shelf registration statement previously filed and declared effective by the SEC. The final prospectus supplement and accompanying prospectus are available on the SEC's website.

Intelligent Bio Solutions (Nasdaq: INBS) has announced the pricing of its public offering of 1,304,348 shares of common stock at $2.00 per share, aiming to raise approximately $2.6 million in gross proceeds before deducting underwriting costs and expenses.

Ladenburg Thalmann & Co. Inc. is serving as the sole bookrunning manager for the offering. The company has granted the underwriter a 45-day option to purchase up to an additional 195,652 shares at the public offering price less underwriting discounts. The offering is expected to close around February 21, 2025.

The net proceeds will be used for working capital and general corporate purposes. The offering is being made through a shelf registration statement filed with the SEC on April 8, 2022, and declared effective on April 20, 2022.